-
Current use of antipsychotic medications by the elderly places them at increased risk for hospitalization for pneumonia.
-
Cognitive impairment in the U.S. population without dementia is found in 22% of those over age 70. This is more than the number of those with Alzheimer's or other dementias alone, and needs to be recognized and addressed in our healthcare of this group.
-
Despite previous positive reports and much lay enthusiasm, omega-3 fatty acid treatment did not prevent Crohn's disease relapse. (Arguments continue as to whether the correct usage should be "Crohn disease" or "Crohn's disease." Most of the literature seems to use the latter designation, and this review will do likewise.)
-
-
Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
Because the consequence of missed pulmonary embolism (PEM) is so grave, it is essential to continue our evolution of tools which maximize diagnostic sensitivity, offer clinical expedience, and minimize risk for the patient.
-
Regadenoson, the first selective A2A adenosine receptor agonist, has been approved for use as a pharmacologic stress agent for nuclear medicine stress testing (radionuclide myocardial perfusion imaging).
-
-
In This Issue: Shingles vaccine added to CDC list of vaccines for adults 60 and older; CDC recommends Tdap for postpartum women; new study suggests sequential therapy with antibiotics for H. pylori may be more effective than standard therapy; FDA Actions.
-